Methods and compositions for modifying the course and severity of neuropsychiatric disorders. The method includes administering a composition to a subject suffering from a neuropsychiatric disorder, wherein the composition includes a substance selected from dextromethadone, dextromethadone metabolites, d-methadol, d-alpha-acetylmethadol, d-alpha-normethadol, l-alpha-normethadol, and pharmaceutically acceptable salts thereof.

Methods and compositions for modifying the course and severity of neuropsychiatric disorders. The method includes administering a composition to a subject suffering from a neuropsychiatric disorder, wherein the composition includes a substance selected from dextromethadone, dextromethadone metabolites, d-methadol, d-alpha-acetylmethadol, d-alpha-normethadol, l-alpha-normethadol, and pharmaceutically acceptable salts thereof.

An antibacterial composition that comprises as active compound at least one light isotope of an element selected from the group which consists of .sup.1H, .sup.12C, .sup.16O, .sup.14N, .sup.39K, .sup.24Mg, .sup.64Zn, .sup.85Rb, .sup.28Si, .sup.54Fe, .sup.92Mo, .sup.74Se, .sup.58Ni, .sup.70Ge, .sup.52Cr, .sup.63Cu, .sup.50V, or combinations thereof, wherein the composition is enriched for the at least one light isotope. A method of treating and preventing bacterial diseases in humans and non-human animals by administering the composition. The use of the said composition in human and veterinary medicine for the prevention and treatment of diseases in humans and non-human animals and also as an antiseptic and disinfectant.

An antibacterial composition that comprises as active compound at least one light isotope of an element selected from the group which consists of .sup.1H, .sup.12C, .sup.16O, .sup.14N, .sup.39K, .sup.24Mg, .sup.64Zn, .sup.85Rb, .sup.28Si, .sup.54Fe, .sup.92Mo, .sup.74Se, .sup.58Ni, .sup.70Ge, .sup.52Cr, .sup.63Cu, .sup.50V, or combinations thereof, wherein the composition is enriched for the at least one light isotope. A method of treating and preventing bacterial diseases in humans and non-human animals by administering the composition. The use of the said composition in human and veterinary medicine for the prevention and treatment of diseases in humans and non-human animals and also as an antiseptic and disinfectant.

A health food for promotion of quality of sleepy and metabolism, comprises the following components with a weight ratio of: 44.93 Milligrams ±25% of Magnesium (Mg), 3.8 Milligrams (±25%) of Zinc (Zn), 40 Micrograms (±25%) of Selenium (Se) and 40 Micrograms (±25%) of Chromium (Cr). Magnesium has the effect to promote ability of cardiovascular disease prevention; zinc can increase the power of mitochondria and enhance the power of metabolism, selenium serves to reduce risks of suffering from cancers and suppress the probability of infection of RNA virus, and Chromium has the effect of reduction of type 2 diabetes. A combination of above mentioned components has the overall effect of promotion of sleep quality, reduction of demand of sleep and increase abilities of diseases preventions.

A health food for promotion of quality of sleepy and metabolism, comprises the following components with a weight ratio of: 44.93 Milligrams ±25% of Magnesium (Mg), 3.8 Milligrams (±25%) of Zinc (Zn), 40 Micrograms (±25%) of Selenium (Se) and 40 Micrograms (±25%) of Chromium (Cr). Magnesium has the effect to promote ability of cardiovascular disease prevention; zinc can increase the power of mitochondria and enhance the power of metabolism, selenium serves to reduce risks of suffering from cancers and suppress the probability of infection of RNA virus, and Chromium has the effect of reduction of type 2 diabetes. A combination of above mentioned components has the overall effect of promotion of sleep quality, reduction of demand of sleep and increase abilities of diseases preventions.

The disclosure provides, inter alia, compositions including cell-nanoparticle constructs and drug loaded nanoparticles, and methods for their use in the treatment of cancer. Also provided are unmodified cisplatin molecules encapsulated by silica nanoparticles, and their use in the treatment of cancer.

The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and/or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.

The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and/or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.

The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and/or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.